B. Riley Securities initiated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $10.00

HC Wainwright & Co. reiterated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $15.00 from $20.00 previously

Cantor Fitzgerald initiated coverage of PDS Biotechnology with a rating of Overweight and set a new price target of $25.00

Chardan Capital reiterated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $15.00 from $11.00 previously

HC Wainwright & Co. reiterated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $20.00 from $8.00 previously

Chardan Capital reiterated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $11.00 from $10.00 previously

HC Wainwright & Co. reiterated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $8.00 from $6.00 previously

Oppenheimer resumed coverage of PDS Biotechnology with a rating of Buy and set a new price target of $7.00

PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the year ended December 31, 2024, and provide a clinical programs update on Thursday, March 27, 2025, at 8:00 a.m. Eastern Time. Conference Call Details Date: March 27, 2025Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)Webcast Registration: Click HereCall Me™ Registration: Click Here (Available 15 minutes prio

Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that it has received the official minutes from its meeting with the U.S. Food and Drug Administration ("FDA") regarding next steps in its planned Phase 3 clinical trial of its Versamune® based investigational immunotherapy designed to stimulate a targeted T cell attack against HPV

PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to provide a clinical program update on Thursday, August 1, 2024, at 8:00 a.m. ET. Conference Call DetailsDate: August 1, 2024Time: 8:00 a.m. ET Dial-in: 1-877-704-4453 or 1-201-389-0920 Webcast Registration: Click HereCall Me™ Registration: Click Here (Available 15 minutes prior to call) About PDS BiotechnologyPDS Biotechnology is a late-stage

Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial As a result, Company to focus late-stage clinical strategy on triple combination of PDS01ADC, PDS0101 (Versamune® HPV) and KEYTRUDA® in advanced head and neck cancer Strong safety profile of IL-12 fused antibody drug conjugate (PDS01ADC) demonstrated to date with data generated in >300 cancer patients; Versamune® HPV tested in >110 HNSCC patients Successful recent meeting with FDA provided clear guidance on trial design and regulatory pathway for pivotal randomized trial of triple combination in recurrent metastatic

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell-activating platforms, today announced that the Company will provide a business update and release financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Following the release, management will host a conference call to review the financial results and provide a business update. Wednesday, March 27, 2024, 8:00 AM ETDomestic: 877-704-4390International: 201-38

Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive cancer patients; published median overall survival of 7-11 months with FDA approved ICI1Announced 2-year overall survival rate of 74% in VERSATILE-002 Phase 2 trial of ICI-naïve HPV16-positive recurrent or metastatic head and neck cancer patients; published 2-year overall survival of less than 30% with FDA approved ICI1Announced interim safety and immune response data for Phase 1/2 clinical trial evaluating docetaxel and PDS01ADC in metastatic prostate cancer patients; PSA decline was seen in all 18 patients and 61% of patients had at least a 60% decrease in PSA

PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced that the Company will release financial results for the third quarter of 2023 on Tuesday, November 14, 2023, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update. Tuesday, November 14, 2023, 8:00 AM ET Domestic: 877-407-3088International: 201-389-0927 Conferen

PRINCETON, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced that the Company will release financial results for the second quarter of 2023 on Monday, August 14, 2023, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update. Monday, August 14, 2023, 8:00 AM ET Domestic: 877-407-3088International: 201-389-0927 Conference ID: 13739270 Webcast: PDS Bio

FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will be hosting a conference call and webcast tomorrow, June 6, 2023, to discuss the promising interim data from the VERSATILE-002 (NCT04260126) Phase 2 clinical trial investigating PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), presented at the 2023 American Society for Clinical Oncology (ASCO) meeting. During the call, management will provide an in-depth review of the 2023 ASCO interim data.

Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, will discuss its financial results for the quarter ended March 31, 2023, and provide a business update on its conference call today. First Quarter and Recent Business Highlights: PDS0101 Lead Drug Candidate VERSATILE-002 Phase 2 open-label, multicenter study of PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUD

PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that three abstracts on Versamune® HPV (PDS0101) have been accepted for presentation at the 2025 American Society of Clinical Oncology ("ASCO") Annual Meeting, taking place May 30-June 3, 2025, in Chicago, Illinois. Details of the presentation are as follows: Title: VERSATILE-003: A Phase 3, Randomized, Open-label Trial of PDS0101 and Pembrolizumab compared with Pembrolizumab for First-Line Treatment of Patients with HPV16-positive Recurr

NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that an abstract submitted by the National Cancer Institute ("NCI") reporting clinical data on PDS01ADC, the Company's IL-12 fused antibody drug conjugate, has been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois. Details of the presentatio

Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a clinical programs update and reported financial results for the full year ended December 31, 2024. "We are pleased with the progress made over the past year and in recent weeks, culminating with the initiation of our VERSATILE-003 Phase 3 clinical trial evaluati

PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025. Updated details of the presentation are as follows: 2025 CAGLA NeauxCancer ConferenceDate: Friday, March 28, 2025Event: Scientific PresentationSession: Innovation TrackTime: 11:00 AM CT (formerly 4 PM CT)Loc

PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the year ended December 31, 2024, and provide a clinical programs update on Thursday, March 27, 2025, at 8:00 a.m. Eastern Time. Conference Call Details Date: March 27, 2025Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)Webcast Registration: Click HereCall Me™ Registration: Click Here (Available 15 minutes prio

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3DIWqav The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through March 18th. To facilitate investor relations scheduling and to view a complete calend

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent #12,201,685 covering methods of using combinations of the Versamune® platform and various immunocytokines, including PDS01ADC recently issued PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug ("IND") applicatio

NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT:   https://bit.ly/4hnure6 It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "We look forward to bringing together innovators from the life sciences sector," s

PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, and the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025. Details of the presentations are as follows: Zacks SCR Life Sciences Virtual Investor ForumDate: Thursday, March 13, 2025Ev

PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the initiation of the VERSATILE-003 Phase 3 clinical trial. The trial is now open to patient enrollment. "We are thrilled to share that the first trial site has been initiated and activation of additional clinical sites continues," said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. "Considering the strength and durability of the clinical responses in our VERSATILE-002 study, we are pleased to get this registra

4 - PDS Biotechnology Corp (0001472091) (Issuer)

4 - PDS Biotechnology Corp (0001472091) (Issuer)

4 - PDS Biotechnology Corp (0001472091) (Issuer)

4 - PDS Biotechnology Corp (0001472091) (Issuer)

4 - PDS Biotechnology Corp (0001472091) (Issuer)

4 - PDS Biotechnology Corp (0001472091) (Issuer)

4 - PDS Biotechnology Corp (0001472091) (Issuer)

4 - PDS Biotechnology Corp (0001472091) (Issuer)

4 - PDS Biotechnology Corp (0001472091) (Issuer)

3 - PDS Biotechnology Corp (0001472091) (Issuer)

PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced the appointment of Stephan Toutain, MS, MBA, as Chief Operating Officer (COO), effective as of May 1, 2024. "We are thrilled to welcome Stephan to the PDS Biotech team as Chief Operating Officer. His invaluable experience spans many aspects of the life sciences industry, from drug development to commercialization, providing a wealth of knowledge to our team," said Frank Bedu-Addo, PhD, Pre

PRINCETON, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or "the Company"), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced the appointment of Kirk V. Shepard, M.D., as Chief Medical Officer, effective January 22, 2024. Dr. Shepard succeeds Lauren V. Wood, M.D., who is retiring from the Company after five years in the role. Dr. Wood will continue to be available to PDS Biotech during a handover period to facilitate the transition of the role to Dr. Shepard. "We are please

Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced the appointment of Lars Boesgaard as Chief Financial Officer (CFO), effective as of December 4, 2023. Mr. Boesgaard succeeds Matthew Hill, who resigned as PDS Biotech's CFO on November 21, 2023, effective December 1, 2023, to pursue other professional endeavors. "We are delighted to welcome Lars to the PDS Biotech team. He is an experienced CFO with

FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T cell activating technologies, today announced that Spencer Brown has joined PDS Biotech as Senior Vice President, General Counsel. Mr. Brown has extensive legal affairs and compliance experience with leading biotechnology, healthcare and pharmaceutical companies. Prior to joining PDS Biotech, Mr. Brown held the position of Senior Vice President, Legal Affairs and Compliance Officer a

FLORHAM PARK, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that Sanjay Zaveri has joined PDS Biotech as Senior Vice President, Business Development. Mr. Zaveri has extensive partnering experience having completed licenses and acquisitions between leading biotechnology and pharmaceutical companies. As PDS Biotech's Senior Vice President of Business Development, he is responsible for business strate

FLORHAM PARK, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced the appointment of Dr. Olivera Finn and Dr. Mark Frohlich to its Scientific Advisory Board. Dr. Olivera Finn is a Distinguished Professor of Immunology at the University of Pittsburgh, School of Medicine. Dr. Finn brings over three decades of expertise in translational research in immunology and oncology, including the discovery of the first tumor-associated protein (antigen) recognized by T-cel

FLORHAM PARK, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the Compensation Committee of the PDS Board of Directors approved the grant of inducement stock options covering an aggregate of 202,800 shares of PDS Biotech’s common stock to the newly appointed Chief Financial Officer, Seth Van Voorhees in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted under PDS Biotech’s 2019 Inducement Plan, which was adopted on June 17, 2019 and

FLORHAM PARK, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the appointment of Seth Van Voorhees, Ph.D. as its new Chief Financial Officer effective January 1, 2021. “Dr. Van Voorhees is a highly accomplished CFO with extensive experience in corporate finance, capital markets, investment banking and licensing. His appointment comes at a time of significant opportunity and growth for our Company. His business and financial expertise will be instrumental in

SC 13G/A - PDS Biotechnology Corp (0001472091) (Subject)

SC 13G - PDS Biotechnology Corp (0001472091) (Subject)

SC 13G/A - PDS Biotechnology Corp (0001472091) (Subject)

SC 13D/A - PDS Biotechnology Corp (0001472091) (Subject)

SC 13G - PDS Biotechnology Corp (0001472091) (Subject)